Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer

Abstract

IntroductionThe integration of diagnostic testing for the presence of a molecular target is of interest to predict successful targeted radionuclide therapy (TRNT). This so-called ‘theranostic’ approach aims to improve personalized treatment based on the molecular characteristics of cancer cells. Moreover, it offers new insights in predicting adverse effects and provides appropriate tools to monitor therapy responses. Recent findings using nanobodies emphasize their potential as theranostic tools in cancer treatment. Nanobodies are recombinant, small antigen-binding fragments that are derived from camelid heavy-chain-only antibodies.Areas covered We review the current status of theranostic approaches in TRNT, with a focus on antibodies, peptides, scaffold proteins and emerging nanobodies. In recent years, nanobodies have been evaluated intensively for molecular imaging. In addition, novel data on TRNT using radiolabeled nanobodies for carcinomas and multiple myeloma highlight their promising opportunities in cancer treatment.Expert opinion We trust that radiolabeled nanobodies will have a future potential as theranostic tools in cancer therapy, both for diagnosis as well as for TRNT.

Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma

“…Because of their small size (<15 kDa), they clear fast from blood and penetrate deep into tissues (20). For imaging of cancer, sdAbs have been directed to a variety of type-I transmembrane cancer cell biomarkers (20)(21)(22). A first-in-human PET study with 68 Ga-labeled anti-HER2 sdAb for breast cancer imaging was recently finalized in our university hospital.…”

Radionuclide 131I labeled reduced graphene oxide for nuclear imaging guided combined radio- and photothermal therapy of cancer

“…Radiation therapy (RT), which relies on the ionizing radiation to control the growth of cancerous cells, has been applied to prevent tumor recurrence before and after surgical removal of primary malignant tumors [1,2]. Nowadays, various radiation sources including X-ray, electron beams and radionuclides, which can be further classified into external and internal radiotherapy, have been widely used in the clinical cancer treatment [3].…”

15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma

“…Nanobodies also have the future potential of serving as diagnostic and theranostic tools in oncology (D'Huyvetter et al 2014). Several approaches have already been developed, such as radiolabeled nanobodies against VEGFR2 and CAIX, and could be evaluated in PHEOs/PGLs.…”